This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Will patients, who are obese and don’t have Type 2 diabetes, ask for the drug for weight loss, and will patients understand the risks? Mounjaro, Lilly’s new diabetes drug, is sure to be in high demand initially after launch, but patients should be aware of its sideeffects. A matter of trust?
A Harvard study found that almost half of Americans are expected to be obese by 2030, accounting for up to 18 percent of healthcare spending on related conditions, ranging from heart disease and stroke to osteoarthritis. . It has to persuade patients to sign up for some heinous sideeffects. Then there is the price.
billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes. This is especially beneficial as a way of decreasing potential sideeffects.
The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant sideeffects that are unappealing to patients. of 7MM sales.
A Phase III trial evaluating TauRx Therapeutics’ oral drug hydromethylthionine mesylate (HMTM), a tau aggression inhibitor, showed the medication continued to improve cognition over a pre-treatment baseline in patients with early Alzheimer’s for the first time. The safety data from the trial was consistent with earlier trial data.
On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related sideeffects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.
How can we help ensure patients continue to take their medications as prescribed? The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue. billion in 2030 at a CAGR of 9.2%. But it is not a simple answer. from 2021 and reach $4.2
Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) sideeffects. This is important for a condition that requires chronic treatment, as poor GI tolerability could adversely affect patients’ quality of life, adherence to treatment and clinical outcomes.
UK-based George Medicines is running a phase 3 trial of GMRx2 – a low-dose formulation of established blood pressure drugs telmisartan, amlodipine, and indapamide – involving 1,500 patients across seven countries. By 2030, it is projected that over 215 million Africans will have hypertension.
The QR code payment market is projected to rise to $35 billion by 2030. A) Aiding Healthcare Professionals (HCPs): Storage of Patient Information: The common method of use of QR codes is in the organization and accessibility of patient records. In essence, patients’ files are all synced to a medical database.
Anti-amyloid beta (Aβ) monoclonal antibody (mAb) donanemab is part of new class of amyloid targeting therapies, and while it can slow Alzheimer’s disease progression by four to seven months, NICE’s independent committee highlighted, they were uncertain about making it available for NHS patients. billion in 2030, respectively.”
Today, there are some noticeable shifts for the better happening on the digital front, largely driven by healthcare consumerism and the demand that healthcare meet patients where they are – on their phones, in their homes, and outside the hospital. Collecting data outside of a care setting can offer valuable insights into day-to-day health.
of patients, while for ARIAH-H the rates were 17% and 0.7%, respectively. He pointed out that services to administer the injections frequently, and the required radiology and clinical monitoring for patients, “will all need to be factored in on top of the simple cost of the drug.” In Clarity AD, the rate of ARIA-E was 12.5%
The QR code payment market is projected to rise to $35 billion by 2030. The hospital waiting room can often have an uncomfortable atmosphere despite the Patient Experience Officer’s best efforts. Here, patients can familiarize themselves with their animal’s caretaker and watch informative or entertaining videos in an easy format.
How patients receive treatment is being revolutionised by advancements in AI and machine learning, the internet of things (IoT) and extended reality, coupled with a growing comfort with digital devices including smartphones and telehealth, as a part of managing one’s care. The global market size is estimated to be more than $95.3bn 1.
Likewise, between 2030 and 2050, the World Health Organization estimates that climate change will be responsible for around 250,000 additional deaths per year. Perhaps this is no surprise – it speaks, after all, to the very heart of the pharmaceutical sector’s purpose: to improve the lives of patients and communities.
This guidance is in line with the WHO’s End TB Strategy, which aims for an 80% fall in worldwide TB incidence and a 90% decrease in TB deaths by 2030, compared with 2015. Each trial will recruit approximately 500 patients. Following this, patients must receive follow-ups to ensure that they do not have a post-treatment relapse.
In our latest podcast, Ideas to Innovation, we speak with Dr. Grace Lomax, the clinical director at Patient Connect, part of Clarivate. In 2017, the same year the SDGs came into effect, the United Nations found that less than half of the global population was covered by essential health services. Dr. Grace Lomax.
from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe sideeffects. from 2023 to 2030. Poised to grow at a CAGR of 29.4% The global pharmacovigilance (PV) market stood at USD 7.80
Eleven medicines, covering key areas such as gene therapy, as well as drugs for obesity and oncology, are anticipated to attain blockbuster status or be therapeutic game-changers globally within five years to 2030, according to the 2025 edition of the Drugs to Watch report.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content